Literature DB >> 26233247

Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery.

Andrew Yaeh1, Tavish Nanda1, Ashish Jani1, Tzlil Rozenblat1, Yasir Qureshi2, Shumaila Saad1, Jeraldine Lesser1, Andrew B Lassman3,4, Steven R Isaacson1,4, Michael B Sisti4,5, Jeffrey N Bruce4,5, Guy M McKhann4,5, Tony J C Wang6,7.   

Abstract

Renal cell carcinoma, sarcoma, and melanoma are considered to be "radioresistant" tumor histologies. Brain metastases (BM) from these tumors are considered unlikely to be controlled using the relatively low doses used in whole brain radiotherapy (WBRT). Our objective was to analyze the efficacy of stereotactic radiosurgery (SRS) on local control and overall survival of BM from radioresistant primary tumors. We reviewed all patients who received Gamma Knife Radiosurgery (GKRS) for BM at Columbia University Medical Center between January 2009 and April 2014. All patients were treated using the Gamma Knife Perfexion System. Dosimetric data was collected from treatment plans and metastases were categorized as radioresistant or not. Response was assessed by reviewing follow-up brain imaging studies and classified according to RECIST. Local control and median overall survival were calculated using the Kaplan-Meier method. In total, 373 tumors were analyzed from 126 patients. Of these tumors, 49 (13.1 %) originated from radioresistant cancers. The overall local control rate in the radioresistant cohort was 89.8 and 90.1 % in the non-radioresistant cohort. Univariate and multivariate analyses demonstrated that radioresistance status of the primary tumor had no statistically significant effect on local control with hazard ratios of 1.0 (p = 1.0, 95 % CI 0.388-2.576) and 0.954 (p = 0.926, 95 % CI 0.349-2.603) respectively. Median overall survival for both radioresistant and non-radioresistant cohorts was 20.0 months, with a p value of 0.926. There was no significant difference in local control of BM from radioresistant and non-radioresistant primary tumors treated with GKRS. Both cohorts showed excellent response and local control, suggesting that SRS upfront or in addition to WBRT may be an appropriate strategy in the treatment of BM from radioresistant cancers. Median overall survival for both cohorts was equal, suggesting that improved local control may be associated with an improvement in long-term survival.

Entities:  

Keywords:  Brain metastases; Gamma knife radiosurgery; Local control; Radioresistance

Mesh:

Year:  2015        PMID: 26233247     DOI: 10.1007/s11060-015-1871-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

Authors:  Hidefumi Aoyama; Masao Tago; Norio Kato; Tatsuya Toyoda; Masahiro Kenjyo; Saeko Hirota; Hiroki Shioura; Taisuke Inomata; Etsuo Kunieda; Kazushige Hayakawa; Keiichi Nakagawa; Gen Kobashi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

3.  Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications.

Authors:  S D Lavine; Z Petrovich; A A Cohen-Gadol; L S Masri; D L Morton; S J O'Day; R Essner; V Zelman; C Yu; G Luxton; M L Apuzzo
Journal:  Neurosurgery       Date:  1999-01       Impact factor: 4.654

4.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

5.  External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center.

Authors:  M Wrónski; M H Maor; B J Davis; R Sawaya; V A Levin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-01       Impact factor: 7.038

6.  Gamma Knife stereotactic radiosurgery for intracranial metastases from conventionally radioresistant primary cancers: outcome analysis of survival and control of brain disease.

Authors:  Anthony H Sin; Raul J Cardenas; Prasad Vannemreddy; Anil Nanda
Journal:  South Med J       Date:  2009-01       Impact factor: 0.954

7.  Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases.

Authors:  Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

8.  Defining the role of radiosurgery in the management of brain metastases.

Authors:  M P Mehta; J M Rozental; A B Levin; T R Mackie; S S Kubsad; M A Gehring; T J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

9.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

10.  The usefulness of stereotactic radiosurgery for radioresistant brain metastases.

Authors:  Hyool Kim; Tae-Young Jung; In-Young Kim; Shin Jung; Kyung-Sub Moon; Seung-Jin Park
Journal:  J Korean Neurosurg Soc       Date:  2013-08-31
View more
  12 in total

1.  Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent disease.

Authors:  Tavish Nanda; Andrew Yaeh; Cheng-Chia Wu; Ashish Jani; Shumaila Saad; Yasir H Qureshi; Keith A Cauley; Jeraldine Lesser; Simon K Cheng; Steven R Isaacson; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Sameer A Sheth; Andrew B Lassman; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-11-23       Impact factor: 4.130

2.  The role of stereotactic radiosurgery and whole brain radiation therapy as primary treatment in the treatment of patients with brain oligometastases - A systematic review.

Authors:  Or Cohen-Inbar; Jason P Sheehan
Journal:  J Radiosurg SBRT       Date:  2016

3.  Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform.

Authors:  Cheng-Chia Wu; Kunal R Chaudhary; Yong Hum Na; David Welch; Paul J Black; Adam M Sonabend; Peter Canoll; Yvonne M Saenger; Tony J C Wang; Cheng-Shie Wuu; Tom K Hei; Simon K Cheng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-05-19       Impact factor: 7.038

4.  Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours.

Authors:  Davide Franceschini; Luca Cozzi; Fiorenza De Rose; Piera Navarria; Ciro Franzese; Tiziana Comito; Cristina Iftode; Angelo Tozzi; Lucia Di Brina; Anna Maria Ascolese; Elena Clerici; Giuseppe D'Agostino; Antonella Fogliata; Marta Scorsetti
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-03       Impact factor: 4.553

Review 5.  Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy.

Authors:  Bassanelli Maria; Viterbo Antonella; Roberto Michela; Giacinti Silvana; Staddon Anita; Aschelter Anna Maria; D'Antonio Chiara; Marchetti Paolo
Journal:  Ther Adv Med Oncol       Date:  2016-07-25       Impact factor: 8.168

Review 6.  Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Authors:  Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2016-10-22       Impact factor: 4.693

7.  Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial.

Authors:  Shady Kotb; Alexandre Detappe; François Lux; Florence Appaix; Emmanuel L Barbier; Vu-Long Tran; Marie Plissonneau; Hélène Gehan; Florence Lefranc; Claire Rodriguez-Lafrasse; Camille Verry; Ross Berbeco; Olivier Tillement; Lucie Sancey
Journal:  Theranostics       Date:  2016-01-20       Impact factor: 11.556

8.  Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.

Authors:  Erik S Anderson; Michael A Postow; Jedd D Wolchok; Robert J Young; Åse Ballangrud; Timothy A Chan; Yoshiya Yamada; Kathryn Beal
Journal:  J Immunother Cancer       Date:  2017-10-17       Impact factor: 13.751

9.  Gamma Knife Radiosurgery for Metastatic Brain Tumors with Exophytic Hemorrhage.

Authors:  Eun Suk Park; Eun Jung Lee; Jung-Ho Yun; Young Hyun Cho; Jeong Hoon Kim; Do Hoon Kwon
Journal:  J Korean Neurosurg Soc       Date:  2018-08-31

10.  Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).

Authors:  Paul Lesueur; Justine Lequesne; Victor Barraux; William Kao; Julien Geffrelot; Jean-Michel Grellard; Jean-Louis Habrand; Evelyne Emery; Brigitte Marie; Juliette Thariat; Dinu Stefan
Journal:  Radiat Oncol       Date:  2018-07-28       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.